1932

Abstract

Prodromal features of the schizophrenia syndrome have been described for a century, and work in the past two decades has produced a substantial literature based on these features to identify individuals at increased risk for developing a psychotic disorder. Sometimes conceptualized as a “risk state” and sometimes as early manifestations of a “disorder,” the work has been conducted with several related but different constructs. Early in the preparation of the fifth edition of the (DSM-5) public comment was sought on the proposal to create a new disorder termed attenuated psychosis syndrome (APS), and a range of issues emerged that generated interesting and important controversies. In this review, these criticisms are fully discussed, the APS concept is explicated; data relating to reliability, validity, and treatment are updated; the heterogeneity of APS is considered; and alternative views of the construct are presented with an emphasis on developmental pattern with timing for primary and secondary prevention and early treatment. Areas of future research are identified, and a potential roadmap for inclusion in DSM-5.1 is traced.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-clinpsy-032813-153645
2014-03-28
2024-06-25
Loading full text...

Full text loading...

/deliver/fulltext/clinpsy/10/1/annurev-clinpsy-032813-153645.html?itemId=/content/journals/10.1146/annurev-clinpsy-032813-153645&mimeType=html&fmt=ahah

Literature Cited

  1. Achim AM, Maziade M, Raymond E, Olivier D, Merette C, Roy MA. 2011. How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant association. Schizophr. Bull. 37:811–21 [Google Scholar]
  2. Addington D, McKenzie E, Addington J, Patten S, Smith H, Adair C. 2005. Performance measures for early psychosis treatment services. Psychiatr. Serv. 56:1570–82 [Google Scholar]
  3. Addington J, Cadenhead KS, Cannon TD, Cornblatt B, McGlashan TH. et al. 2007. North American Prodrome Longitudinal Study: a collaborative multisite approach to prodromal schizophrenia research. Schizophr. Bull. 33:665–72 [Google Scholar]
  4. Addington J, Epstein I, Liu L, French P, Boydell KM, Zipursky RB. 2011. A randomized controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophr. Res. 125:54–61 [Google Scholar]
  5. Am. Psychiatr. Assoc 1980. Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: Am. Psychiatr. Publ, 3rd ed.. [Google Scholar]
  6. Am. Psychiatr. Assoc 1994. Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: Am. Psychiatr. Publ, 4th ed.. [Google Scholar]
  7. Am. Psychiatr. Assoc 2013. Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: Am. Psychiatr. Publ, 5th ed.. [Google Scholar]
  8. Amminger GP, Schafer MR, Papageorgiou K, Klier CM, Cotton SM. et al. 2010. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch. Gen. Psychiatry 67:146–54 [Google Scholar]
  9. Antithromb. Trialists' Collab 2002. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324:71–86 [Google Scholar]
  10. Bechdolf A, Muller H, Stutzer H, Wagner M, Maier W. et al. 2011. Rationale and baseline characteristics of PREVENT: a second-generation intervention trial in subjects at-risk (prodromal) of developing first-episode psychosis evaluating cognitive behavior therapy, aripiprazole, and placebo for the prevention of psychosis. Schizophr. Bull. 37:Suppl. 2S111–21 [Google Scholar]
  11. Buckley PF, Miller BJ, Lehrer DS, Castle DJ. 2009. Psychiatric comorbidities and schizophrenia. Schizophr. Bull. 35:383–402 [Google Scholar]
  12. Carletti F, Woolley JB, Bhattacharyya S, Perez-Iglesias R, Fusar Poli P. et al. 2012. Alterations in white matter evident before the onset of psychosis. Schizophr. Bull. 38:1170–79 [Google Scholar]
  13. Carpenter WT, van Os J. 2011. Should attenuated psychosis syndrome be a DSM-5 diagnosis?. Am. J. Psychiatry 168:460–63 [Google Scholar]
  14. Carrion RE, McLaughlin D, Goldberg TE, Auther AM, Olsen RH. et al. 2013. Prediction of functional outcome in individuals at clinical high risk for psychosis. JAMA Psychiatry 70:1133–42 [Google Scholar]
  15. Catts VS, Fung SJ, Long LE, Joshi D, Vercammen A. et al. 2013. Rethinking schizophrenia in the context of normal neurodevelopment. Front. Cell Neurosci. 7:60 [Google Scholar]
  16. Clarke DE, Narrow WE, Regier DA, Kuramoto SJ, Kupfer DJ. et al. 2013. DSM-5 field trials in the United States and Canada, part I: study design, sampling strategy, implementation, and analytic approaches. Am. J. Psychiatry 170:43–58 [Google Scholar]
  17. Daly CA, De Stavola B, Sendon JL, Tavazzi L, Boersma E. et al. 2006. Predicting prognosis in stable angina—results from the Euro heart survey of stable angina: prospective observational study. BMJ 332:262–67 [Google Scholar]
  18. De Masi S, Sampaolo L, Mele A, Morciano C, Cappello S. et al. 2008. The Italian guidelines for early intervention in schizophrenia: development and conclusions. Early Interv. Psychiatry 2:291–302 [Google Scholar]
  19. Egerton A, Chaddock CA, Winton-Brown TT, Bloomfield MA, Bhattacharyya S. et al. 2013. Presynaptic striatal dopamine dysfunction in people at ultra-high risk for psychosis: findings in a second cohort. Biol. Psychiatry 74:2106–12 [Google Scholar]
  20. Falloon IR. 1992. Early intervention for first episodes of schizophrenia: a preliminary exploration. Psychiatry 55:4–15 [Google Scholar]
  21. Falloon IR, Kydd RR, Coverdale JH, Laidlaw TM. 1996. Early detection and intervention for initial episodes of schizophrenia. Schizophr. Bull. 22:271–82 [Google Scholar]
  22. Feinberg I. 1982. Schizophrenia: caused by a fault in programmed synaptic elimination during adolescence?. J. Psychiatr. Res. 17:319–34 [Google Scholar]
  23. Feinberg I. 1990. Cortical pruning and the development of schizophrenia. Schizophr. Bull. 16:4567–70 [Google Scholar]
  24. Fusar-Poli P, Bechdolf A, Taylor M, Bonoldi I, Carpenter W. et al. 2013a. At risk for schizophrenic or affective psychosis? A meta-analysis of ICD/DSM diagnostic outcomes in individuals at high clinical risk. Schizophr. Bull. 39:923–32 [Google Scholar]
  25. Fusar-Poli P, Bonoldi I, Yung AR, Borgwardt S, Kempton M. et al. 2012a. Predicting psychosis: a meta-analysis of transition outcomes in individuals at high clinical risk. Arch. Gen. Psychiatry 69:1–10 [Google Scholar]
  26. Fusar-Poli P, Borgwardt S, Bechdolf A, Addington J, Riecher-Rossler A. et al. 2013b. The psychosis high-risk state: a comprehensive state-of-the-art review. JAMA Psychiatry 70:107–20 [Google Scholar]
  27. Fusar-Poli P, Borgwardt S, Crescini A, D'Este G, Kempton M. et al. 2011a. Neuroanatomy of vulnerability to psychosis: a voxel-based meta-analysis. Neurosci. Biobehav. Rev. 35:1175–85 [Google Scholar]
  28. Fusar-Poli P, Byrne M, Badger S, McGuire PK, Valmaggia L. 2013c. Outreach and support in South London (OASIS), 2001–2011: ten years of early diagnosis and treatment for young individuals at clinical high risk for psychosis. Eur. Psychiatry 28:315–26 [Google Scholar]
  29. Fusar-Poli P, Deste G, Smieskova R, Barlati G, Yung AR. et al. 2012b. Cognitive functioning in prodromal psychosis: a meta-analysis. Arch. Gen. Psychiatry 69:562–71 [Google Scholar]
  30. Fusar-Poli P, Hobson R, Raduelli M, Balottin U. 2012c. Reliability and validity of the Comprehensive Assessment of the At Risk Mental State, Italian version (CAARMS-I). Curr. Pharm. Des. 18:386–91 [Google Scholar]
  31. Fusar-Poli P, Howes OD, Allen P, Broome M, Valli I. et al. 2010. Abnormal frontostriatal interactions in people with prodromal signs of psychosis: a multimodal imaging study. Arch. Gen. Psychiatry 67:683–91 [Google Scholar]
  32. Fusar-Poli P, Howes OD, Allen P, Broome M, Valli I. et al. 2011c. Abnormal prefrontal activation directly related to pre-synaptic striatal dopamine dysfunction in people at clinical high risk for psychosis. Mol. Psychiatry 16:67–75 [Google Scholar]
  33. Fusar-Poli P, Kempton MJ, Rosenheck RA. 2013d. Efficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trials. Int. Clin. Psychopharmacol. 28:57–66 [Google Scholar]
  34. Fusar-Poli P, Meyer-Lindenberg A. 2013. Striatal presynaptic dopamine in schizophrenia, part II: meta-analysis of [18F/11C]-DOPA PET studies. Schizophr. Bull. 39:33–42 [Google Scholar]
  35. Fusar-Poli P, Nelson B, Valmaggia L, Yung A, McGuire P. 2012d. Comorbid depressive and anxiety disorders in 509 individuals with an at risk mental state: impact on psychopathology and transition to psychosis. Schizophr. Bull. doi:10.1093/schbul/sbs136 [Google Scholar]
  36. Fusar-Poli P, Perez J, Broome M, Borgwardt S, Placentino A. et al. 2007. Neurofunctional correlates of vulnerability to psychosis: a systematic review and meta-analysis. Neurosci. Biobehav. Rev. 31:465–84 [Google Scholar]
  37. Fusar-Poli P, Politi P. 2008. Paul Eugen Bleuler and the birth of schizophrenia (1908). Am. J. Psychiatry 165:111407 [Google Scholar]
  38. Fusar-Poli P, Stone J, Broome M, Valli I, Mechelli A. et al. 2011d. Thalamic glutamate level predicts cortical response during executive functioning in subjects at high risk for psychosis. Arch. Gen. Psychiatry 68:881–90 [Google Scholar]
  39. Fusar-Poli P, Van Os J. 2013. Lost in transition: setting psychosis threshold in prodromal research. Acta Psychiatr. Scand. 127:248–52 [Google Scholar]
  40. Fusar-Poli P, Yung AR, McGorry P, van Os J. 2013e. Lessons learned from the psychosis high-risk state: towards a general staging model of prodromal intervention. Psychol. Med. 18:1–8 [Google Scholar]
  41. Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K. et al. 2006. Mild cognitive impairment. Lancet 367:1262–70 [Google Scholar]
  42. Giuliano A, Li H, Mesholam-Gately R, Sorensonb S, Woodberry K, Seidman L. 2012. Neurocognition in the psychosis risk syndrome: a quantitative and qualitative review. Curr. Pharm. Des. 18:399–415 [Google Scholar]
  43. Hafner H, Maurer K, Loffler W, an der Heiden W, Munk-Jorgensen P. et al. 1998. The ABC Schizophrenia Study: a preliminary overview of the results. Soc. Psychiatry Psychiatr. Epidemiol. 33:380–86 [Google Scholar]
  44. Hafner H, Maurer K, Loffler W, Riecher-Rossler A. 1993. The influence of age and sex on the onset and early course of schizophrenia. Br. J. Psychiatry 162:80–86 [Google Scholar]
  45. Hafner H, Riecher-Rossler A, Maurer K, Fatkenheuer B, Loffler W. 1992. First onset and early symptomatology of schizophrenia. A chapter of epidemiological and neurobiological research into age and sex differences. Eur. Arch. Psychiatry Clin. Neurosci. 242:109–18 [Google Scholar]
  46. Heckers S, Barch DM, Bustillo J, Gaebel W, Gur R. et al. 2013. Structure of the psychotic disorders classification in DSM-5. Schizophr. Res. 150:11–14 [Google Scholar]
  47. Hoffman RE, McGlashan TH. 1993. Parallel distributed processing and the emergence of schizophrenic symptoms. Schizophr. Bull. 19:119–40 [Google Scholar]
  48. Howes OD, Bose SK, Turkheimer F, Valli I, Egerton A. et al. 2011. Dopamine synthesis capacity before onset of psychosis: a prospective [18F]-DOPA PET imaging study. Am. J. Psychiatry 168:1311–17 [Google Scholar]
  49. Howes OD, Kambeitz J, Kim E, Stahl D, Slifstein M. et al. 2012. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch. Gen. Psychiatry 69:776–86 [Google Scholar]
  50. Howes OD, Montgomery A, Asselin M, Valli I, Tabraham P. et al. 2009. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch. Gen. Psychiatry 66:13–20 [Google Scholar]
  51. Huber G, Gross G. 1989. The concept of basic symptoms in schizophrenic and schizoaffective psychoses. Recent Prog. Med. 80:646–52 [Google Scholar]
  52. Int. Early Psychos. Assoc. Writ. Group 2005. International clinical practice guidelines for early psychosis. Br. J. Psychiatry Suppl. 48:S120–24 [Google Scholar]
  53. Jackson HJ, McGorry PD, McKenzie D. 1994. The reliability of DSM-III prodromal symptoms in first-episode psychotic patients. Acta Psychiatr. Scand. 90:375–78 [Google Scholar]
  54. Jacobs E, Kline E, Schiffman J. 2011. Practitioner perceptions of attenuated psychosis syndrome. Schizophr. Res. 131:24–30 [Google Scholar]
  55. Jacobs E, Kline E, Schiffman J. 2012. Defining treatment as usual for attenuated psychosis syndrome: a survey of community practitioners. Psychiatr. Serv. 63:1252–56 [Google Scholar]
  56. Jessen F, Scherk H, Traber F, Theyson S, Berning J. et al. 2006. Proton magnetic resonance spectroscopy in subjects at risk for schizophrenia. Schizophr. Res. 87:81–88 [Google Scholar]
  57. Jung MH, Jang JH, Kang DH, Choi JS, Shin NY. et al. 2010. The reliability and validity of the Korean version of the Structured Interview for Prodromal Syndromes. Psychiatry Invest. 7:257–63 [Google Scholar]
  58. Kaymaz N, Drukker M, Lieb R, Wittchen HU, Werbeloff N. et al. 2012. Do subthreshold psychotic experiences predict clinical outcomes in unselected non-help-seeking population-based samples? A systematic review and meta-analysis, enriched with new results. Psychol. Med. 42:2239–53 [Google Scholar]
  59. Kelleher I, Murtagh A, Molloy C, Roddy S, Clarke MC. et al. 2012. Identification and characterization of prodromal risk syndromes in young adolescents in the community: a population-based clinical interview study. Schizophr. Bull. 38:239–46 [Google Scholar]
  60. Klosterkötter J, Gross G, Huber G, Wieneke A, Steinmeyer EM, Schultze-Lutter F. 1997. Evaluation of the “Bonn Scale for the Assessment of Basic Symptoms—BSABS” as an instrument for the assessment of schizophrenia proneness: a review of recent findings. Neurol. Psychiatry Brain Res. 5:137–50 [Google Scholar]
  61. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM. et al. 2002. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346:393–403 [Google Scholar]
  62. Koehler K, Guth W, Grimm G. 1977. First-rank symptoms of schizophrenia in Schneider-oriented German centers. Arch. Gen. Psychiatry 34:7810–13 [Google Scholar]
  63. Koutsouleris N, Meisenzahl EM, Davatzikos C, Bottlender R, Frodl T. et al. 2009. Use of neuroanatomical pattern classification to identify subjects in at-risk mental states of psychosis and predict disease transition. Arch. Gen. Psychiatry 66:700–12 [Google Scholar]
  64. Kraepelin E. 1971. Dementia Praecox and Paraphrenia Huntington, NY: Krieger [Google Scholar]
  65. Larsen TK, McGlashan TH, Johannessen JO, Vibe-Hansen L. 1996. First-episode schizophrenia: II. Premorbid patterns by gender. Schizophr. Bull. 22:257–69 [Google Scholar]
  66. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL. et al. 2004. Practice guideline for the treatment of patients with schizophrenia, second edition. Am. J. Psychiatry 161:1–56 [Google Scholar]
  67. Lencz T, Smith CW, Auther A, Correll CU, Cornblatt B. 2004. Nonspecific and attenuated negative symptoms in patients at clinical high-risk for schizophrenia. Schizophr. Res. 68:37–48 [Google Scholar]
  68. Levey A, Lah J, Goldstein F, Steenland K, Bliwise D. 2006. Mild cognitive impairment: an opportunity to identify patients at high risk for progression to Alzheimer's disease. Clin. Ther. 28:991–1001 [Google Scholar]
  69. Lin A, Wood SJ, Nelson B, Brewer WJ, Spiliotacopoulos D. et al. 2011. Neurocognitive predictors of functional outcome two to 13 years after identification as ultra-high risk for psychosis. Schizophr. Res. 132:1–7 [Google Scholar]
  70. Mayer-Gross W. 1932. Die Klinik der Schizophrenie. Handbuch der Geisteskrankheiten O. Bumke. Berlin: Springer [Google Scholar]
  71. McGlashan TH. 1996. Early detection and intervention in schizophrenia: research. Schizophr. Bull. 22:327–45 [Google Scholar]
  72. McGlashan TH, Hoffman RE. 2000. Schizophrenia as a disorder of developmentally reduced synaptic connectivity. Arch. Gen. Psychiatry 57:637–48 [Google Scholar]
  73. McGlashan TH, Johannessen JO. 1996. Early detection and intervention with schizophrenia: rationale. Schizophr. Bull. 22:201–22 [Google Scholar]
  74. McGlashan TH, Walsh BC, Woods SW. 2010. The Psychosis-Risk Syndrome: Handbook for Diagnosis and Follow-Up New York: Oxford Univ. Press [Google Scholar]
  75. McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T. et al. 2006. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am. J. Psychiatry 163:790–99 [Google Scholar]
  76. McGorry P. 2005. “Every me and every you”: responding to the hidden challenge of mental illness in Australia. Australas. Psychiatry 13:3–15 [Google Scholar]
  77. McGorry P, van Os J. 2013. Redeeming diagnosis in psychiatry: timing versus specificity. Lancet 381:343–45 [Google Scholar]
  78. McGorry PD, Yung AR, Phillips LJ, Yuen HP, Francey S. et al. 2002. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch. Gen. Psychiatry 59:921–28 [Google Scholar]
  79. McGrath J, Saha S, Welham J, El Saadi O, MacCauley C, Chant D. 2004. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Med. 2:13 [Google Scholar]
  80. McGuire P, Howes OD, Stone J, Fusar-Poli P. 2008. Functional neuroimaging in schizophrenia: diagnosis and drug discovery. Trends Pharmacol. Sci. 29:91–98 [Google Scholar]
  81. McMillan KA, Enns MW, Cox BJ, Sareen J. 2009. Comorbidity of Axis I and II mental disorders with schizophrenia and psychotic disorders: findings from the National Epidemiologic Survey on Alcohol and Related Conditions. Can. J. Psychiatry 54:477–86 [Google Scholar]
  82. Mechelli A, Riecher-Rossler A, Meisenzahl EM, Tognin S, Wood SJ. et al. 2011. Neuroanatomical abnormalities that predate the onset of psychosis: a multicenter study. Arch. Gen. Psychiatry 68:489–95 [Google Scholar]
  83. Miller TJ, McGlashan TH, Rosen JL, Cadenhead K, Cannon T. et al. 2003. Prodromal assessment with the Structured Interview for Prodromal Syndromes and the Scale of Prodromal Symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr. Bull. 29:703–15 [Google Scholar]
  84. Miller TJ, McGlashan TH, Rosen JL, Somjee L, Markovich PJ. et al. 2002. Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: preliminary evidence of interrater reliability and predictive validity. Am. J. Psychiatry 159:863–65 [Google Scholar]
  85. Miyakoshi T, Matsumoto K, Ito F, Ohmuro N, Matsuoka H. 2009. Application of the Comprehensive Assessment of At-Risk Mental States (CAARMS) to the Japanese population: reliability and validity of the Japanese version of the CAARMS. Early Interv. Psychiatry 3:123–30 [Google Scholar]
  86. Modinos G, Allen P, Frascarelli M, Tognin S, Valmaggia L. et al. 2014. Are we really mapping psychosis risk? Neuroanatomical signature of affective disorders in subjects at ultra high risk. Psychol. Med. In press [Google Scholar]
  87. Morrison AP, French P, Walford L, Lewis SW, Kilcommons A. et al. 2004. Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. Br. J. Psychiatry 185:291–97 [Google Scholar]
  88. Narrow WE, Clarke DE, Kuramoto SJ, Kraemer HC, Kupfer DJ. et al. 2013. DSM-5 field trials in the United States and Canada, part III: development and reliability testing of a cross-cutting symptom assessment for DSM-5. Am. J. Psychiatry 170:71–82 [Google Scholar]
  89. Nelson B, Yuen K, Yung AR. 2011. Ultra high risk (UHR) for psychosis criteria: Are there different levels of risk for transition to psychosis?. Schizophr. Res. 125:62–68 [Google Scholar]
  90. Niendam TA, Jalbrzikowski M, Bearden CE. 2009. Exploring predictors of outcome in the psychosis prodrome: implications for early identification and intervention. Neuropsychol. Rev. 19:280–93 [Google Scholar]
  91. Olin SC, Mednick SA. 1996. Risk factors of psychosis: identifying vulnerable populations premorbidly. Schizophr. Bull. 22:223–40 [Google Scholar]
  92. Oshima K, Okimura T, Yukizane T, Yasumi K, Iwawaki A. et al. 2010. Reliability and diagnostic validity for schizophrenia of the Japanese version of the Bonn Scale for Assessment of Basic Symptoms (BSABS). J. Med. Dent. Sci. 57:83–94 [Google Scholar]
  93. Pantelis C, Velakoulis D, McGorry PD, Wood SJ, Suckling J. et al. 2003. Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet 361:281–88 [Google Scholar]
  94. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R. et al. 2005. Vitamin E and donepezil for the treatment of mild cognitive impairment. N. Engl. J. Med. 352:2379–88 [Google Scholar]
  95. Pettersson-Yeo W, Benetti S, Marquand AF, Dell'acqua F, Williams SC. et al. 2013. Using genetic, cognitive and multi-modal neuroimaging data to identify ultra-high-risk and first-episode psychosis at the individual level. Psychol. Med. 43:2547–62 [Google Scholar]
  96. Phillips LJ, Velakoulis D, Pantelis C, Wood S, Yuen HP. et al. 2002. Non-reduction in hippocampal volume is associated with higher risk of psychosis. Schizophr. Res. 58:145–58 [Google Scholar]
  97. Pillmann F, Haring A, Balzuweit S, Bloink R, Marneros A. 2002. The concordance of ICD-10 acute and transient psychosis and DSM-IV brief psychotic disorder. Psychol. Med. 32:525–33 [Google Scholar]
  98. Regier DA, Narrow WE, Clarke DE, Kraemer HC, Kuramoto SJ. et al. 2013. DSM-5 field trials in the United States and Canada, part II: test-retest reliability of selected categorical diagnoses. Am. J. Psychiatry 170:59–70 [Google Scholar]
  99. Riecher-Rossler A, Aston J, Ventura J, Merlo M, Borgwardt S. et al. 2008. The Basel Screening Instrument for Psychosis (BSIP): development, structure, reliability and validity. (From German.) Fortschr. Neurol. Psychiatr. 76:207–16 [Google Scholar]
  100. Rietdijk J, Klaassen R, Ising H, Dragt S, Nieman D. et al. 2012. Detection of people at risk of developing a first psychosis: comparison of two recruitment strategies. Acta Psychiatr. Scand. 126:21–30 [Google Scholar]
  101. Romm KL, Rossberg JI, Berg AO, Barrett EA, Faerden A. et al. 2010. Depression and depressive symptoms in first episode psychosis. J. Nerv. Ment. Dis. 198:67–71 [Google Scholar]
  102. Ruhrmann S, Schultze-Lutter F, Klosterkotter J. 2010a. Probably at-risk, but certainly ill—advocating the introduction of a psychosis spectrum disorder in DSM-V. Schizophr. Res. 120:23–37 [Google Scholar]
  103. Ruhrmann S, Schultze-Lutter F, Salokangas RK, Heinimaa M, Linszen D. et al. 2010b. Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European prediction of psychosis study. Arch. Gen. Psychiatry 67:241–51 [Google Scholar]
  104. Schimmelmann BG, Michel C, Schaffner N, Schultze-Lutter F. 2011. What percentage of people in the general population satisfies the current clinical at-risk criteria of psychosis?. Schizophr. Res. 125:99–100 [Google Scholar]
  105. Schultze-Lutter F. 2009. Subjective symptoms of schizophrenia in research and the clinic: the basic symptom concept. Schizophr. Bull. 35:5–8 [Google Scholar]
  106. Schultze-Lutter F, Addington J, Ruhrmann S, Klosterkotter J. 2007. Schizophrenia Proneness Instrument, Adult Version (SPI-A) Rome: Giovanni Fioriti Editore [Google Scholar]
  107. Schultze-Lutter F, Schimmelmann BG, Ruhrmann S. 2011. The near Babylonian speech confusion in early detection of psychosis. Schizophr. Bull. 37:653–55 [Google Scholar]
  108. Schultze-Lutter F, Schimmelmann BG, Ruhrmann S, Michel C. 2013. “A rose is a rose is a rose,” but at-risk criteria differ. Psychopathology 46:75–87 [Google Scholar]
  109. Seidman LJ, Giuliano AJ, Meyer EC, Addington J, Cadenhead KS. et al. 2010. Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosis. Arch. Gen. Psychiatry 67:578–88 [Google Scholar]
  110. Smieskova R, Fusar-Poli P, Allen P, Bendfeldt K, Stieglitz R. et al. 2010. Neuroimaging predictors of transition to psychosis—a systematic review and meta-analysis. Neurosci. Biobehav. Rev. 34:1207–22 [Google Scholar]
  111. Stafford MR, Jackson H, Mayo-Wilson E, Morrison AP, Kendall T. 2013. Early interventions to prevent psychosis: systematic review and meta-analysis. BMJ 346:f185 [Google Scholar]
  112. Stone J, Day F, Tsagaraki H, Valli I, McLean M. et al. 2009. Glutamate dysfunction in people with prodromal symptoms of psychosis: relationship to gray matter volume. Mol. Psychiatry 66:533–39 [Google Scholar]
  113. Sullivan HS. 1994. The onset of schizophrenia. 1927. Am. J. Psychiatry 151:134–39 [Google Scholar]
  114. Tabak AG, Herder C, Rathmann W, Brunner EJ, Kivimaki M. 2012. Prediabetes: a high-risk state for diabetes development. Lancet 379:2279–90 [Google Scholar]
  115. Tandon R, Heckers S, Bustillo J, Barch DM, Gaebel W. et al. 2013. Catatonia in DSM-5. Schizophr. Res. 150:26–30 [Google Scholar]
  116. Tsuang MT, Van Os J, Tandon R, Barch DM, Bustillo J. et al. 2013. Attenuated psychosis syndrome in DSM-5. Schizophr. Res. 150:31–35 [Google Scholar]
  117. Van Os J, Linscott R, Myin-Germeys I, Delespaul P, Krabbendam L. 2009. A systematic review and meta-analysis of the psychosis continuum: evidence for a psychosis proneness-persistence-impairment model of psychotic disorder. Psychol. Med. 39:179–95 [Google Scholar]
  118. Velakoulis D, Wood SJ, Wong MT, McGorry PD, Yung A. et al. 2006. Hippocampal and amygdala volumes according to psychosis stage and diagnosis: a magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals. Arch. Gen. Psychiatry 63:139–49 [Google Scholar]
  119. Vollmer-Larsen A, Handest P, Parnas J. 2007. Reliability of measuring anomalous experience: the Bonn Scale for the Assessment of Basic Symptoms. Psychopathology 40:345–48 [Google Scholar]
  120. Wiffen PJ, Moore RA. 1996. Demonstrating effectiveness—the concept of numbers-needed-to-treat. J. Clin. Pharm. Ther. 21:23–27 [Google Scholar]
  121. Winton-Brown TT, Harvey SB, McGuire PK. 2011. The diagnostic significance of BLIPS (brief limited intermittent psychotic symptoms) in psychosis. Schizophr. Res. 131:256–57 [Google Scholar]
  122. Wood SJ, Berger G, Velakoulis D, Phillips LJ, McGorry PD. et al. 2003. Proton magnetic resonance spectroscopy in first episode psychosis and ultra high-risk individuals. Schizophr. Bull. 29:831–43 [Google Scholar]
  123. Woodberry KA, Giuliano AJ, Seidman LJ. 2008. Premorbid IQ in schizophrenia: a meta-analytic review. Am. J. Psychiatry 165:579–87 [Google Scholar]
  124. Woods S, Walsh B, McGlashan T. 2012. Diagnostic reliability and validity of the proposed DSM-5 attenuated psychosis syndrome. Early Interv. Psychiatry 6:Suppl. 133 (Abstr.) [Google Scholar]
  125. Woods SW, Addington J, Bearden CE, Cadenhead KS, Cannon TD. et al. 2013. Psychotropic medication use in youth at high risk for psychosis: comparison of baseline data from two research cohorts 1998–2005 and 2008–2011. Schizophr. Res. 148:99–104 [Google Scholar]
  126. Woods SW, Addington J, Cadenhead KS, Cannon TD, Cornblatt BA. et al. 2009. Validity of the prodromal risk syndrome for first psychosis: findings from the North American Prodrome Longitudinal Study. Schizophr. Bull. 35:894–908 [Google Scholar]
  127. Woods SW, Miller TJ, McGlashan TH. 2001. The “prodromal” patient: both symptomatic and at-risk. CNS Spectr. 6:223–32 [Google Scholar]
  128. Woods SW, Walsh BC, Saksa JR, McGlashan TH. 2010. The case for including attenuated psychotic symptoms syndrome in DSM-5 as a psychosis risk syndrome. Schizophr. Res. 123:199–207 [Google Scholar]
  129. Yucel M, Wood SJ, Phillips LJ, Stuart GW, Smith DJ. et al. 2003. Morphology of the anterior cingulate cortex in young men at ultra-high risk of developing a psychotic illness. Br. J. Psychiatry 182:518–24 [Google Scholar]
  130. Yung AR. 2003. Commentary. The schizophrenia prodrome: a high-risk concept. Schizophr. Bull. 29:859–65 [Google Scholar]
  131. Yung AR, McGorry PD. 1996. The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophr. Bull. 22:353–70 [Google Scholar]
  132. Yung AR, Nelson B, Stanford C, Simmons MB, Cosgrave EM. et al. 2008. Validation of “prodromal” criteria to detect individuals at ultra high risk of psychosis: 2 year follow-up. Schizophr. Res. 105:10–17 [Google Scholar]
  133. Yung AR, Nelson B, Thompson A, Wood SJ. 2010. The psychosis threshold in ultra high risk (prodromal) research: Is it valid?. Schizophr. Res. 120:1–6 [Google Scholar]
  134. Yung AR, Phillips LJ, Nelson B, Francey SM, PanYuen H. et al. 2011. Randomized controlled trial of interventions for young people at ultra high risk for psychosis: 6-month analysis. J. Clin. Psychiatry 72:430–40 [Google Scholar]
  135. Yung AR, Phillips LJ, Yuen HP, Francey SM, McFarlane CA. et al. 2003. Psychosis prediction: 12-month follow up of a high-risk (“prodromal”) group. Schizophr. Res. 60:21–32 [Google Scholar]
  136. Yung AR, Woods SW, Ruhrmann S, Addington J, Schultze-Lutter F. et al. 2012. Whither the attenuated psychosis syndrome?. Schizophr. Bull. 38:1130–34 [Google Scholar]
  137. Yung AR, Yuen HP, McGorry PD, Phillips LJ, Kelly D. et al. 2005. Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. Aust. N. Z. J. Psychiatry 39:964–71 [Google Scholar]
/content/journals/10.1146/annurev-clinpsy-032813-153645
Loading
/content/journals/10.1146/annurev-clinpsy-032813-153645
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error